cyrilzakka/clinical-trials huggingface dataset:
Prevalence of Undiagnosed Chronic Obstructive Pulmonary Disease Sufferers in the Region of Murcia

The purpose of this study is determine the prevalence of undiagnosed Chronic Obstructive Pulmonary Disease (COPD) in population served and with exposure to cigarettes in the Region of Murcia

COPD is a serious, chronic and very disabling, associated with smoking and aging. Therefore it is a preventable and treatable process. It is know to be a pathology under diagnosed and when diagnosis, this is done in advanced stage, resulting to rise to more complication and more severe, in a addition to a high social and economic cost.

Therefore, take out an epidemiological study, observational, multicentre, whose main objective is estimate the prevalence of undiagnosed COPD in population served between 40 and 70 years and exposure to cigarettes in the Region of Murcia.

Other objectives are estimate the proportion of patients already diagnosed, identifying risk factors associated with not previous diagnosis of COPD and describe the history of symptoms in them. Description of therapeutic manage and motivation to give up smoking.

The study was carried out with 120 researcher doctors and 120 researcher nurses from 40 health centers in the Region of Murcia.

Each researcher will select 10 patients for the main objective and 10 for objectives related to manage of COPD.

Eligibility Criteria:
Inclusion Criteria:

1. Aged between 40 and 70 years of both sexes
2. With a history of smoking (current or past)
3. Do not diagnosed with COPD at the time of completion of study

Exclusion Criteria:

1. Prior diagnosis of COPD or Asthma
2. A condition prevents performing spirometry
3. Patients displaced

For those diagnosed with COPD:

Inclusion Criteria:

* Subject treated in CS there is explicit evidence for the disease

Exclusion Criteria:

* Subjects who at the time of the consultation arouse suspicion of previously undiagnosed COPD
Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer

Malignant pleural or pericardial effusion is common in lung cancer, and intrapleural drugs injection is important in the treatment. Non- cytotoxic drugs include those with a sclerosing effect that produces pleurodesis, which is easy to cause severe chest pain despite of no influence on the following chemotherapy. Tumor angiogenesis is important in producing MPE. Bevacizumab has been administrated locally in treating optic nerve sickness successfully by anti-VEGF mechanism. So we hypothesize that intrapleural bevacizumab is also effective in treating MPE.

Inclusion Criteria:

1. Histological or cytological diagnosis of non-small cell lung cancer.
2. Cytological diagnosis of malignant pleural or pericardial effusion (MPE)
3. Symptomatic MPE evaluated by researchers
4. Unsuitable for or reject systemic therapy of tumor
5. Continuous TKI treatment after TKI-resistance
6. Estimated survival of more than 3 months. 7.18 years or older

Exclusion Criteria:

1. Current or recent (within 10 days prior to treatment) use the full amount of inhibition of platelet function, anticoagulants or thrombolytic therapy, which allows prophylactic anticoagulants
2. Be allergic to bevacizumab
3. Pregnant or lactating woman
4. Pleural or pericardial infection

Eligibility Criteria:
Inclusion Criteria:

1. Histological or cytological diagnosis of non-small cell lung cancer.
2. Cytological diagnosis of malignant pleural or pericardial effusion (MPE)
3. Symptomatic MPE evaluated by researchers
4. Unsuitable for or reject systemic therapy of tumor
5. Estimated survival of more than 3 months. 6.18 years or older

Exclusion Criteria:

1. Current or recent (within 10 days prior to treatment) use the full amount of inhibition of platelet function, anticoagulants or thrombolytic therapy, which allows prophylactic anticoagulants
2. Be allergic to bevacizumab
3. Pregnant or lactating woman
4. Pleural or pericardial infection
Evaluation of Efficacy and Safety of Ialuset Cream and Gauze in Second-degree Burns on Child

Observational retrospective monocentric study occured in the univeristy hospital center of Bensançon the department of pediatric surgery.

Data of patients treated in the hospital between January 2016 and January 2019 have been collected.

Coordinator investigator have put in place a protocol care for children with second degree burns since 2016.

It consists in detersion and cleaning of wound, application of ialuset cream and gauzepad (hyaluronic acid) during 21 days. After 21 days if patients are not healed, physician consider to perform grafting

Eligibility Criteria:
Inclusion Criteria:

* second-degree burns
* less than 20% of the body surface
* less than 15 years old
* treated within 24 hours
* 1st line of treatment with ialuset
* treated at the center between 2016 and 2019

Exclusion Criteria:

* patient who refused data collection
Cell-phone Assisted Postpartum Counseling on the Use of Long-acting Reversible Contraceptives

Unintended and closely spaced pregnancies are a major public health problem that affects not only the individuals directly involved but also the society indirectly. It increases the risks of infants with adverse outcomes such as preterm, low birth weight and small for gestational age. Pregnancy occurring within six months of the last delivery holds a 7.5-fold increased risk for induced abortion, a 3.3-fold increase in miscarriage and a 1.6-fold increased risk of stillbirth. But, use of contraceptive methods has been shown to reduce unwanted pregnancy, high fertility and maternal mortality rates.


Eligibility Criteria:
Inclusion Criteria:

* Women who deliver a live birth at greater than 28 week's gestation.
* Women desire birth spacing for more than one year
* Women who were holding and /or one of her family hold a cell-phone and accept to receive messages and phone calls to remind her with her contraceptive program

Exclusion Criteria:

* Women who refuse to participate in the study.
* Women aren't able to respond to the questionnaire due to their health status.
* Anticipation of difficulty of subsequent communication with the women
* Women with contraindications of using long acting reversible contraception ( contraindicated if intrauterine device or implant use)
Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture

In this randomised controlled study the investigators intended to compare the analgesic effects of EMLA and\\or nitrous oxide in children submitted to lumbar puncture.

It is a randomized controlled clinical trial, double blinded, with the purpose to compare the use of EMLA - local anesthetic (lidocaine and prilocaine), and or nitrous oxide at 50% in oxygen (Livopan®) to prevent and treat pain in pediatric patients aged four to 16 years old submitted to lumbar puncture for intrathecal chemotherapy. Pain was assessed using the Wong Baker faces scale and the visual numeric scale during six observational periods: baseline; three minutes after gas administration and before the first attempt of lumbar puncture; during the first lumbar puncture attempt; during the chemotherapy administration; during needle remove and three minutes after gas interruption. All the studied procedures will have clinical indication and will not be held by the researcher. The children was random divided within three groups A, B and C as follow: Group A (n=16)EMLA + Livopan; Group B (n=19)EMLA + gas placebo (oxygen); Group C (n=17) Livopan® + placebo cream.

Primary outcome was the detection of a difference of 20% or more in the visual numeric scale between the three treatment groups during the first attempt of lumbar puncture.

Eligibility Criteria:
Inclusion Criteria:

* Age between four and 14 years;
* Not present cognitive disabilities;
* Necessity to perform the clinical procedure;
* Accordance in participating in the study.

Exclusion Criteria:

* Continuity skin lesion in the procedure site;
* Metahemoglobinemia;
* Neuromuscular disability;
* Presence of pneumothorax, emphysema, intra-abdominal infection, cranioencephalic traumatism, otitis media, sinusitis and intracranial hypertension;
* Vitamin B12 known deficits;
* Urgency for the procedure;
* Disagreement in participating of the project;
* Patients in use of Dapsone.
A Study to Assess the Pharmacokinetics of Methotrexate Given With and Without AZD9056 in Rheumatoid Arthritis Patients

The main aim of this clinical study is to investigate whether the blood concentration of methotrexate changes when AZD9056 is co- administered together with methotrexate.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with rheumatoid arthritis
* Currently on Methotrexate treatment
* Provision of informed consent

Exclusion Criteria:

* History of malignancy (except for treated squamous and basal cell carcinoma of the skin more than 5 years prior to entry)
* Patients who were taking prescription of medications listed below:

Medications that are hepatic enzyme inducers and that were inhibitors of cytochrome P450, Lovastatin

* Leflunomide, hydroxychloroquine, cyclosporin or anti-tumour necrosis factor therapies within 90 days of Visit 1, or treatment with rituximab within 1 year before Visit 1
Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors

The study participant is being asked to be in a research study called LEGACY, because you were treated for high-risk neuroblastoma (HR-NBL).

Primary Objective

To determine the feasibility of conducting comprehensive evaluations, leveraging the established SJLIFE (St. Jude Lifetime Cohort Study) study infrastructure, in survivors of HR-NBL (high-risk neuroblastoma) who are greater than 2 years from completion of contemporary therapy and were previously treated at SJCRH (St. Jude Children's Research Hospital).

Exploratory Objectives

* To describe the health outcomes of survivors of HR-NBL previously treated at SJCRH with contemporary era therapy who are greater than 2 years from completion of therapy.
* To describe the relationship between patient outcomes and social determinants of health (SDOH) in survivors of HR-NBL previously treated at SJCRH with contemporary era therapy who are greater than 2 years from completion of therapy.

The study participant will have blood tests, tests to measure how your nervous system and stomach works, and an ultrasound of your liver for this study. The researchers will test how well your heart and blood vessels are working.

Eligibility Criteria:
Inclusion Criteria:

* Participants were diagnosed with neuroblastoma at \< 18 years of age and categorized as high-risk at that time, according to INSS26 or INRGSS27 criteria.
* Participants were treated for HR-NBL at SJCRH on NB2012 or as per NB2012.
* Participants are ≥ 2 years from completion of therapy. Participants are 5 years of age or older.
* Participant or legal guardian is able and willing to give informed consent.
* Participants may choose to participate in all or a fraction of the proposed assessments; refusal to participate in some aspects of the study will not preclude their inclusion.
* Participants must also complete enrollment on SJLIFE.

Exclusion Criteria:

* Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
* Participants who had relapsed or refractory disease during or following completion of modern era treatment for HR-NBL.
* Participants who are pregnant or breastfeeding.
* Participants who are unable to read and understand English
Robotic Versus Laparoscopic Low Anterior Resection for Rectal Cancer

Prospective randomized trial comparing robotic versus laparoscopic Low anterior resection for rectal cancer.

Primary endpoint: Compare urinary dysfunction between robotic and laparoscopic approach.

Prospective randomized trial comparing robotic versus laparoscopic Low anterior resection for rectal cancer.

The Aim of the study is to compare two surgical approaches (robotic versus laparoscopic) for rectal cancer treatment regarding functional outcomes (sexual and urinary dysfunctions), quality of life, post operative outcomes and oncologic outcomes.

Patients with the diagnosis of T3 mid and low rectal cancer will be randomized to robotic or laparoscopic procedure after neoadjuvant chemoradiation. Quality of life questionnaires and Urodynamic test will be applied before and after the surgical procedures.

Eligibility Criteria:
Inclusion Criteria:

* Mid or low Rectal Adenocarcinoma
* Performance Status (ECOG) 0 - 2

Exclusion Criteria:

* Metastatic disease
* Congestive heart failure
* Renal failure
* Diabetes
* Pregnancy
* Neurologic disorders
* Alfa blockers user
* Patients who are candidates to APR ( Abdomino-perineal resection)
Exercise Training Using an App on Physical Cardiovascular Function Individuals With Post-covid-19 Syndrome

The aim of this study is to assess the effect of a physical exercise program via a mobile application on functional parameters in individuals with post-COVID-19 syndrome. This is a clinical trial involving 60 individuals with post-COVID syndrome who will be randomly assigned to either a control group (physical activity guideline) or an experimental group (app-based training).


Eligibility Criteria:
Inclusion Criteria:

* Laboratory diagnosis of COVID-19
* Fatigue ≥ 8 points on the Chalder Scale and/or dyspnea 2-4 on the Modified Medical Research Council
* Have access to a smartphone
* Have no contraindications for exercise practice
* Have ability to sit and stand and maintain balance while standing
* Have preserved cognitive function
* Have no risk of falls according to the Morse Fall Scale
Clinical, Radiographical, Histological Evaluation and Blood Flow Analysis of Alveolar Ridge Preservation

With alveolar ridge preservation (ARP) ridge resorption following extraction may be reduced. Several materials and techniques have been advocated for ARP. The aim of our randomised clinical trial is to evaluate the efficacy of extraction side development technique (XSD) and autogenous tooth bone graft (ATB) for ARP.

A three armed clinical study will be established. According to the sample size calculation, every arm will contain 21 participants. The first group is the socket seal group. In the second group we aim to combine the socket seal and XSD technique. In the third group the XSD technique will be combined with the ATB material. The primary outcome is the alveolar ridge width change in millimeter, measured immediately after the tooth extraction and after 6 months at the reentry procedure. The change in alveolar ridge width and vertical dimensional alterations will be also measured as secondary outcomes on the CBCT at baseline and after 6 months. Further secondary outcomes are the monitoring of gingival microvascularization, monitoring of flap revascularization by Laser Speckle Contrast Imaging and assessment of soft tissue volumetric changes by intraoral scanning and histomorphometric evaluation of the volumetric percentage of newly formed bone, connective tissue and graft material after a 6-month healing period in a core biopsy taken at the time of implant placement.

Hypothesis: The XSD and XSD+ATB groups are expected to have less pronounced horizontal width losses. XSD group is expected to produce the highest graft turnover.

Eligibility Criteria:
Inclusion Criteria:

* Women and men Patients over 18 years Co-operative patients with good individual oral hygiene (FMBS: 25%\>) Patients with periodontal disease in treatment or under treatment with minimal active inflammation (FMPS: 25%\>)

Local criteria:

Teeth with a hopeless prognosis with advanced periodontal or endo-periodontal defects, which are restored with implant prosthesis EDS 3-4 extraction defects after tooth extraction

Exclusion Criteria:

* Infectious diseases (HBV, HCV, HIV, CoV-2019...) Current chemotherapy or radiotherapy Previous radiation therapy to the head and neck region (in the last 2 years) Untreated insulin dependent diabetes mellitus Clinically significant osteoporosis or other systemic disease affecting bone metabolism Clinically significant circulatory disorder e.g.: decompensated cardiac failure Haemodynamically significant valvular heart failure or myocardial infarction within the last 3 months Clinically significant coagulopathy Current or previous systemic corticosteroid therapy (in the last 2 months) Current or previous systemic bisphosphonate therapy (beyond 30 days) Pregnant or breastfeeding women Smoking (max 5 cigarettes per day) Drug addiction, alcoholism
A Single Centre, Randomised, Comparative, Blinded Wear Test of Two Adhesives on the AQUACEL® Foam Adhesive Dressing

AQUACEL® foam adhesive dressing is a sterile Hydrofiber® foam wound dressing consisting of a waterproof outer polyurethane film, and a multi-layered absorbent pad, having a silicone adhesive border. The multi-layered absorbent pad contains a layer of polyurethane foam and a non-woven wound contact layer of Hydrofiber® (NaCMC). This dressing product was launched in 2012. A new source of silicone adhesive is now under assessment for this product. This Healthy Volunteer Wear test will form part of the Design Validation for this change in supplier and is required to confirm that the new Silicone Adhesive trilaminate supplier can coat the silicone adhesive to provide comparable adhesive dressing performance in terms of wear time, ease of use and with a similar safety profile in relation to the skin.


Eligibility Criteria:
Inclusion Criteria:

* Provide written informed consent
* Be a healthy volunteer and be over 18 years of age
* Be willing to attend two scheduled visits for application and removal of the device and adverse event review
* Have healthy unbroken skin

Exclusion Criteria:

* Subjects with a history of sensitivity to any one of the components of the device being studied
* Female subjects who are currently pregnant or lactating
* Subjects who are not willing and able to attend the 'clinic' for the required assessments
* Subjects with excessive hair on their backs
* Subjects who have any other medical condition which, according to the investigator justifies exclusion from the study
Database of All Patients With Microbiologically Proven Mycobacteria Tuberculosis Infection

Prospective data collection of all patients with microbiologically proven mycobacteria tuberculosis infection treated at Singapore General Hospital.

Tuberculosis currently infects one third of the world's population and is responsible for killing approximately 2 million individuals annually. This is a major public health concern worldwide, and there has been a huge impetus to implement strategies for better tuberculosis control.

The investigators have established a system to track all patients with microbiologically proven tuberculosis treated at Singapore General Hospital, with vigilant recording and reporting systems, from the first instance when patients were diagnosed to the time they have completed anti-tuberculosis chemotherapy. The investigators endeavour to use this system to improve patient care by adopting patient-supportive approaches that lead to high compliance rates and best possible outcomes of treatment.

Eligibility Criteria:
Inclusion Criteria:

1) All patients with microbiologically proven mycobacteria tuberculosis infection treated at the Singapore General Hospital.
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease

This is a study of infliximab (Remicade) in subjects with Crohn's disease

Crohn's disease is a disease characterized by inflammation (the changes that happen when tissues in the body are injured) and ulceration (formation of pus) of the bowel. The purpose of this study is to investigate the safety and therapeutic effect of two different doses of an anti-TNFα (tumor necrosis factor) antibody (a protein) given multiple times compared to a single dose followed by placebo (inactive substance). The name of the antibody is infliximab (Remicade) The goal of the study is to evaluate whether patients respond longer to a single dose of infliximab or to repeated doses of infliximab.

Subjects will receive an infusion of infliximab at week 0 followed by infusions of infliximab or placebo at weeks 2, 6, 14 and every 8 weeks until week 54. Patients who lose response are eligible for additional infliximab treatment.

Eligibility Criteria:
Inclusion Criteria:

* Men and women \>=18 years of age
* Diagnosis of Crohn's
* Crohn's disease of at least 3 months duration, with colitis, ileitis, or ileocolitis, confirmed by radiography or endoscopy

Exclusion Criteria:

* Local manifestations of Crohn's disease such as strictures, abscesses, or other disease
* Surgery for bowel diversion with placement of a stoma within 3 months prior to beginning the study
* Positive stool culture
FOP Nutrition Label in Campus Cafeteria

This study evaluates the impact of the introduction of a front-of-pack nutrition label on foods and beverages sold in a campus cafeteria in France on the nutritional quality of purchases.

The introduction of front-of-package nutrition labelling is thought to help consumers making healthier food choices at the point-of-purchase.

Recently, the French government has selected the Nutri-Score as single front-of-pack nutrition label.

Evaluations of the Nutri-Score suggest it is in helping consumers making healthier choices. However, its impact in vulnerable populations has not yet been tested. Students are thought to be a vulnerable population due to their limited resources and to their unhealthy food choices.

The objective of the present study is to investigate the impact of the introduction of the Nutri-Score in campus cafeterias on the nutritional quality of food purchases. The intervention is conducted during several months, with a control period without front-of-pack nutrition labelling at the beginning of the university year.

Data on purchases is collected regularly through receipts, and the nutritional quality of purchases is evaluated over time between the intervention situation and the control situation.

Eligibility Criteria:
Inclusion Criteria:

* All subjects purchasing foods or beverages in the selected campus cafeteria

Exclusion Criteria:

* None No individual data is collected. Only purchases data is collected (cash register sales data)